Background: The ability of immunometric methods to identify anti-topoisomerase I (Scl70) antibodies is controversial. We wished to quantify the performance of the currently available commercial systems for the assay of anti-topoisomerase I antibodies in a large multicenter study. Methods: Fifty Italian clinical laboratories analyzed 36 serum samples: 27 from individuals with scleroderma/ systemic sclerosis, and 9 from a control group. The scleroderma/systemic sclerosis samples were positive in our laboratories by both ELISA and immunoblot (IB), and the control samples were negative. The laboratories used 42 immunoenzymatic (ELISA), 21 IB, 3 counterim-munoelectrophoresis, and 2 dot-blot methods, produced by 23 different manufacturers. Results: We obtained 2389 results. The ELISA methods showed 99.2% specificity and 97.2% sensitivity for detection of anti-Scl70 antibodies. For IB methods, specificity was 97.6% and sensitivity was 96.1%. The Western-blot method had poor analytical specificity (27% false positives for anti-extractable nuclear antigen antibodies other than anti-Scl70). Conclusions: Excluding Western blots, commercial ELISA and IB reagents as used in clinical laboratories have a sensitivity and a specificity >95% for determination of anti-Scl70 antibodies. . A preliminary report of this work, entitled "Evaluation of commercial ELISA, CIE and IB assays for the detection of anti-topoisomerase I antibodies: results of a multicentric study" [Clin Chem 1999;45(Suppl S6):A152], was presented as Abstract 538 at the 51st AACC Annual Meeting,
The anti-topoisomerase I antibodies (anti-topo I and anti-Scl70) are serological markers of diffuse systemic sclerosis (1 ) and among its fundamental diagnostic-classification criteria (2, 3 ) . This rare but serious disease also involves very high social and economic costs (4 ) , and the contribution of the autoimmunology laboratory to its diagnosis is essential, thus requiring very high quality analysis. Studies conducted by other workers and our group (5) (6) (7) (8) (9) (10) (11) (12) that addressed the reliability of the immunometric methods in identifying anti-Scl70 antibodies have furnished discordant results, with very variable sensitivities and specificities. Indeed, this phenomenon was confirmed by a recent cooperative study (13 ) that evidenced remarkable differences in sensitivity (range, 20 -100%) and specificity (range, 85-100%) although CDC/WHO referral sera were used (14 ) . Moreover, in addition to the differences in the designs of the above studies, the variations encountered might also be explained by the diverse characteristics and numbers of the patients examined as well as differences in the type of laboratory involved and the reagents used. In addition, most of these studies involved selected reference laboratories that used home-made methods, whereas most clinical laboratories use only commercial reagents.
In recent years, the use of antigenic substrates obtained with molecular biology techniques and the optimization of methods for the extraction and purification of native antigens have contributed to a more precise characterization and identification of these and other autoantibodies indicative of autoimmune diseases. Moreover, the continuous development of analytical techniques has made possible the use of new commercial tests for the determination of the various autoantibody specificities in an ever increasing number of laboratories, thus requiring continuous verification of quality. For this reason, the Study Group on the Diagnosis of Autoimmune Diseases of the Italian Society of Laboratory Medicine has performed an extensive multicenter study involving hospital clinical laboratories to analyze serum samples from patients affected by systemic sclerosis, using numerous commercial methods and reagent set to define present-day reliability in determining anti-topoisomerase I autoantibodies.
Materials and Methods
Fifty clinical laboratories in 14 Italian regions participated in this study that included the determination of antiextractable nuclear antigen (anti-ENA) 10 antibodies in 36 serum samples, 27 of which were obtained from patients with a clinical diagnosis of scleroderma/systemic sclerosis (SSc), according to the criteria of the American College of Rheumatology (15 ) . Sixteen of these samples were obtained from subjects with diffuse cutaneous SSc (anti-Scl70 positive and anti-centromere negative), and 11 were from patients with limited cutaneous SSc (anti-Scl70 negative and anti-centromere positive). Two diffuse cutaneous SSc sera also displayed a simultaneous reactivity for Ro/SSA. The expected antibody specificity was defined not only in reference to the clinical diagnosis, but also on the basis of preliminary results obtained with two different methods [immunoenzymatic (ELISA) and immunoblot (IB) assays] in the four laboratories that collected the test samples; only the samples that were positive with both methods were included in the study. The control group consisted of sera from three patients with systemic lupus erythematosus (one with anti-RNP and anti-Sm, one with anti-RNP, and one with anti-Ro/SSA), three patients with Epstein-Barr virus infection, and three healthy subjects. The aliquoted sera were stored at Ϫ85°C until they were shipped. The participating laboratories were not given any clinical information and were asked to use their usual reagents and analytical systems to determine anti-ENA antibodies.
The 50 participating laboratories conducted 68 series of antibody determinations for a total of 2389 results. The number of series exceeds that of the participants because several laboratories used more than one method: 42 laboratories used ELISA methods (61.8% of the tests conducted); 21 used IB (30.9%), 3 used counterimmunoelectrophoresis (CIE; 4.4%), and 2 used the dot-blot method (2.9%). The reagents were purchased from 23 different manufacturers (listed in Table 1 ). Only one laboratory used an in-house CIE. Statistical analyses were conducted by calculating the sensitivity of each method and reagent set in detecting anti-Scl70 antibodies in the 16 diffuse cutaneous SSc samples, and the specificity in the other 20 samples in which this antibody was absent. We also evaluated analytical specificity, i.e., the number of false positives that were recorded for other anti-ENA antibodies (e.g., anti-RNP, anti-Sm, anti-Ro, anti-La, and anti-Jo1) in sera in which such positivities were not expected. Moreover, in reference to the IB methods, data were elaborated by separately evaluating the two different types of commercially available reagents: the simplified IB (for which we prefer to use the terms line-blot or bar-blot) (16 ), in which 
Results
For all of the methods used, the sensitivity and specificity for anti-Scl70 were 96.9% and 98.6%, respectively ( Table  2 ). Detailed analyses of the performances of the single reagent set, subdivided according to method, are shown in Tables 3-T4 -T5, 4, and 5 for ELISA, IB, and CIE methods, respectively.
elisa method (1481 results)
For anti-Scl70 detection, the specificity was excellent (99.2%) and the sensitivity was good (97.2%). Although it was reported that the systems using recombinant antigens have a better sensitivity than those using native antigens (17 ) , this observation was not confirmed in this study; the mean sensitivity of the 30 laboratories that used native antigens was better than that obtained by the 12 laboratories that used recombinant antigens (98.3% vs 89.4%). Specificity data obtained with the two types of antigen preparations overlapped (99.4% vs 98.3%).
ib method (729 results)
The performance of the reagents utilized in this method was slightly lower than that of the ELISA methods: specificity was 97.6%, and sensitivity was 96.1% for anti-Scl70. Bar-blot and Western-blot methods did not demonstrate different specificities (false positives, 2.4% vs 2.5%) or sensitivities (false negatives, 4.3% vs 3.5%) for anti-Scl70 (Table 4) ; however, remarkable differences emerged regarding analytical specificity because of the high number of false positives for anti-ENA antibodies other than anti-Scl70 obtained with the Western-blot method (23%) compared with the bar-blot method (7.8%; Table 6 ).
cie method (108 results)
Although specificity was quite good (96.7%), sensitivity was poor (72.9%) because of the single test conducted with in-house reagents whose sensitivity was seen to be entirely insufficient (68.7% false negatives; Table 5 ). When this in-house method was excluded and only the commercial ones considered, sensitivity and specificity (93.8% and 95%, respectively) were comparable to other methods.
dot-blot method (71 results)
The best performance was obtained with this method, which showed 100% sensitivity and specificity. However, this finding should be considered with caution because of the small number of laboratories and observations involved.
Discussion
Anti-topoisomerase I antibody is specific for patients affected by scleroderma (18 ) . The prevalence is ϳ40%, but the range is very wide (3-75%) (19, 20 ) , and highest values are observed in patients with the diffuse form for which it is the diagnostic antibody (21, 22 ) . Its presence has been associated with a poorer prognosis and increased pulmonary involvement (23, 24 ) . The early and correct identification of this antibody is thus crucial in both the diagnostic and prognostic phases of the disease and requires very accurate data from the autoimmunology laboratory. The objective of this study, therefore, was to evaluate the sensitivities and specificities of the various methods/reagent sets now on the market and the variability among autoimmunology laboratories in assaying the anti-topoisomerase I antibody.
Unlike some previous studies that had difficulty in identifying this type of antibody (6, 10, 12, 13 ) , the excellent results in terms of both sensitivity and specificity obtained with all the methods/reagent sets used in this study allow us to state that, in general, the commercial systems for determining anti-Scl70 antibodies are reliable. The immunoenzymatic methods, which constituted 60% of the methods/reagent sets used, were determinant in reaching such high efficiency and produced the best results.
It is worth mentioning that the reagents made up of native antigens (obtained from either HEp-2 human cells or bovine or rabbit thymus) yielded better results in terms of sensitivity than reagents containing recombinant antigens (obtained from both eukaryotic and prokaryotic systems), whereas no substantial differences in terms of specificity were observed. This means that the consistent improvement in the techniques of purification of the native antigens, at least as far as Scl70 antigen is concerned, has allowed the production of sufficiently pure preparations, devoid of significant antigenic contamination, while maintaining the characteristics of molecular identity unchanged. The sensitivity and specificity thus obtained are comparable, if not superior, to those of preparations using proteins expressed by recombinant DNA technology.
Concerning analytical specificity, good performance was obtained with all of the methods evaluated with the exception of Western blot, which demonstrated poor specificity, suggesting that interpretative difficulties remain the main problem in assigning antibody positivity. That this difficulty in interpretation is attributable not only to the capacity and experience of the operator, but also to an intrinsic problem in the method appears evident from the following observation. One of the four producers of Western-blot methods who furnished the material to the laboratories has a computerized system for reading the strips by means of a scanner and a software application for the interpretation of the strips. Of the four laboratories that used this reagent, two read the strips with a manual method and two used an automated system, and no substantial differences in terms of specificity emerged; indeed, in both situations there was a high number of false positives (27%; data not shown). This means that even the use of automated systems cannot resolve the problem inherent in this methodology, which undoubtedly is an extremely valid tool for the identification of rare or atypical antibody patterns but has a lower specificity than other methods.
The data for the CIE and dot-blot methods do not permit a reliable judgment given the small number of laboratories that used these methods. Although CIE together with double immunodiffusion has represented the most widespread method for years, its further use seems unlikely mostly because of its poor sensitivity for some autoantibodies; on the other hand, the dot-blot method offers ease of performance as well as direct interpretation, and produced excellent results, features that predict its much wider use in clinical laboratories.
In agreement with the recommendations of the European Consensus Group (6 ) and the guidelines proposed by our group (25 ) , which support the need to use two different methods to identify anti-ENA antibodies, the use of two methods in series should have increased the sensitivity, reducing by one-half the number of false negatives. Indeed, almost one-half of the false negatives recorded in this study occurred with only one of the four methods used.
From a careful examination of the results of this study, it is also possible to draw other conclusions that are helpful for a correct interpretation of the findings, as well as applicable to all external quality assessment studies of this type. First, the expected unreliability of an isolated laboratory that furnished results that were clearly anomalous compared with the general mean, and especially with other laboratories that used the same reagent, confirms that the variance related to the operator is an important part of the total variability. Second, despite the high number of observations, the data are not distributed homogeneously among the various reagent sets, and great caution must be taken in interpreting results obtained with reagent sets for which few data are available. Finally, the lack of a reference method for the anti-ENA antibodies that would allow assignment of a reliable value is one of the main problems that must be faced in the planning and interpretation of results of external quality assessment studies; only the use of sure positive samples with a medium-high antibody titer can obviate this important methodological bias, even if the use of test sera with low antibody titer and values distributed near the threshold of positivity of the methods is more advantageous for evaluating the accuracy of the analytical systems.
In conclusion, this study demonstrated that the commercial reagents used in clinical laboratories for the determination of anti-topoisomerase I antibody have acceptable reliability. In particular, specificity was excellent (98.6%) and sensitivity was good (96.9%). Among the various methods, ELISA presents the best characteristics of accuracy; among the blot methods, Western blot lacks sufficient analytical specificity. It is likely that the realization of national external quality assessment programs will lead to a further improvement in analytical quality, evidencing and correcting the few cases of unreliability related to reagents and/or laboratories.
